Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

It was about 2 in the morning when Claudilio Cruz, a member of a road crew spreading asphalt on U.S. 1 in the affluent Miami suburb of Pinecrest, heard frantic honking. When he looked up he was ...

A Florida woman caught 60 snakes in the state's annual 10-day challenge to eliminate the invasive Burmese python species wreaking havoc with the Everglades ecosystem. More than 900 people participated ...

The 2025 Python Challenge removed a record 294 invasive Burmese pythons from Florida ecosystems. The winner, Taylor Stanberry, removed 60 Burmese pythons and took home a $10,000 prize. The 10-day ...

Residents of downtown Los Angeles were recently shocked to discover a gigantic 20-foot python in a dumpster near an apartment complex. Locals originally thought the snake was fake, but further ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Burmese pythons, while non-venomous, can inflict painful bites with sharp teeth, causing significant bleeding. The annual Florida Python Challenge offers over $25,000 in prizes to hunters removing ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...